We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 172

Data protection: defining innovative drug in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994

Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board

Apotex v Sanofi, case management directions on the late disclosure of documents or information

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question

Apotex v. Canada (Minister of Health)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 28 2009

Apotex brought a judicial review of the Minister’s refusal to issue a NOC regarding its version of aspirin

Sanofi-Aventis v Pharmascience; 55.2 proceeding; motion to limit NOA based on issue estoppel; October 17, 2007 - ramipril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 25 2007

The innovator brought a motion seeking a determination that the generic was precluded from making further allegations of invalidity by the doctrines of abuse of process, res judicata andor issue estoppel, on the basis that the same generic company had made a previous allegation of invalidity that had been found to have no merit

PMPRB guidelines and reporting requirements in effect for 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 22 2010

The Patented Medicine Prices Review Board (PMPRB) released new Guidelines in 2009, including the new pricing tests the Board will apply for patented medicines

Eli Lilly Canada and PMPRB reach agreement on the price of Forteo

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 10 2007

On July 6, 2007, the PMPRB announced that it has approved a Voluntary Compliance Undertaking by Eli Lilly Canada with respect to Forteo

Pfizer v Apotex; decision on the merits of a 55.2 proceeding; January 4, 2008; drug: atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • February 7 2008

The Trial Division found the patent at issue to be invalid as it did not meet the test for a valid selection, and it claimed subject matter that was already the subject of a previous patent

Strategic risk management for biotechnology companies

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, Global
  • -
  • August 1 2008

Ernst & Young has released a report identifying the top 10 strategic risks facing biotechnology companies over the next 5 years

New regulations respecting benefits and promotional allowances in Québec

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 16 2007

The Government of Québec has introduced new regulations under the Act Respecting Prescription Drug Insurance governing the rebates and other benefits offered by drug manufacturers to pharmacists

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy